Showing 49–64 of 67 results
The Oncomine Myelodysplastic Syndrome (MDS) Panel detects genetic mutations linked to MDS and blood cancers. Accurate, next-generation sequencing. Book your test today.
The Oncomine Myeloproliferative Neoplasm (MPN) Panel is a cutting-edge genetic test that analyzes key mutations in JAK2, CALR, and MPL, the genes most commonly linked to myeloproliferative disorders. Using advanced next-generation sequencing (NGS), this test provides a highly accurate and efficient way to diagnose and classify MPNs, even when only small or degraded samples are available (as little as 10 ng of DNA or RNA).
The Oncotype DX Breast Cancer (ML) Test is a genomic assay that analyzes the activity of 21 genes in a breast cancer tumor to predict the risk of recurrence and the potential benefit of chemotherapy. Designed for early-stage, hormone receptor-positive, HER2-negative breast cancer patients, it provides a Recurrence Score® result that helps guide personalized treatment decisions. Key benefits include reducing unnecessary chemotherapy, improving patient outcomes, and offering evidence-based insights backed by extensive clinical validation.
PCR for HLA-B27 (EDTA) is a molecular diagnostic test used to detect the HLA-B27 gene, which is strongly associated with autoimmune disorders like ankylosing spondylitis and other spondyloarthropathies. Utilizing Polymerase Chain Reaction (PCR) technology, this test offers high sensitivity and specificity, ensuring accurate and reliable results.
The PD-L1 (22C3) Dako CPS (IHC) test is an immunohistochemistry (IHC) assay designed to assess PD-L1 expression in tumor and immune cells using the Combined Positive Score (CPS). It is FDA-approved as a companion diagnostic for multiple cancer therapies, ensuring precise patient selection for immune checkpoint inhibitors. The test utilizes the 22C3 monoclonal antibody, providing high sensitivity and specificity in detecting PD-L1 expression. Its standardized scoring system (CPS) enhances reproducibility and clinical decision-making, making it a trusted tool for oncologists. The Dako platform ensures consistent, high-quality staining, supporting accurate and reliable results for personalized cancer treatment.
PredictLife Test is a cutting-edge DNA-based health and longevity assessment that provides personalized insights into your genetic predispositions, lifestyle risks, and potential health outcomes. Using advanced AI and genomic analysis, it evaluates factors like disease risks, aging patterns, nutrition, and fitness optimization.
The Prothrombin Mutation Analysis is a genetic test designed to detect the G20210A mutation in the prothrombin (F2) gene, a key risk factor for inherited thrombophilia. This highly accurate, DNA-based assay identifies individuals with increased risk of abnormal blood clotting, aiding in the diagnosis and management of thrombotic disorders.
The **Ros1 – Fish Test** is a highly sensitive and reliable fluorescence in situ hybridization (FISH) assay designed for the detection of **ROS1 gene rearrangements** in tumor samples. This test is crucial for identifying patients who may benefit from targeted therapies, particularly in **non-small cell lung cancer (NSCLC)**. Key features include **high specificity and accuracy**, rapid turnaround time, and **direct visualization of gene rearrangements** at the cellular level. Its benefits include **early and precise diagnosis**, enabling personalized treatment decisions and improving patient outcomes. The **unique selling point** of the Ros1 – Fish Test is its **proven clinical utility in guiding targeted therapy selection**, making it an essential tool for oncologists and pathologists in precision medicine.
Get the SCA Comprehensive Profile Test in Dubai to diagnose spinocerebellar ataxia types 1,2,3,6,7,12. Blood-based DNA test. Results in 15–20 days. Book now!
Get the SCA-8 (Spinocerebellar Ataxia Type 8) genetic test in Dubai to identify hereditary ataxia. Blood-based DNA analysis. Results in 15–20 days. Book now!
The Somatic HRR (Homologous Recombination Repair) Panel is a cutting-edge genomic test that analyzes tumor tissue for mutations in DNA repair genes — helping oncologists detect aggressive cancers early, assess treatment response, and recommend personalized therapies like PARP inhibitors.
Get the SMA Genetic Test in Dubai to detect SMN1 gene mutations. Early screening for newborns & couples. Accurate, fast results. Book your test today!